Chemo-immunotherapy as first-line treatment for small-cell lung cancer. [Review] (Record no. 6118)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02474nam a22003497a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 210217s20202020 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1758-8340 |
024 ## - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1177_1758835920980365 [pii] |
024 ## - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1177/1758835920980365 [doi] |
024 ## - OTHER STANDARD IDENTIFIER | |
Standard number or code | PMC7750570 [pmc] |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
PMID | 33414848 |
245 ## - TITLE STATEMENT | |
Title | Chemo-immunotherapy as first-line treatment for small-cell lung cancer. [Review] |
251 ## - Source | |
Source | Therapeutic Advances in Medical Oncology. 12:1758835920980365, 2020. |
252 ## - Abbreviated Source | |
Abbreviated source | Ther Adv Med Oncol. 12:1758835920980365, 2020. |
253 ## - Journal Name | |
Journal name | Therapeutic advances in medical oncology |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Year | 2020 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Manufacturer | FY2021 |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
Publication status | epublish |
266 ## - Date added to catalog | |
Date added to catalog | 2021-02-17 |
520 ## - SUMMARY, ETC. | |
Abstract | Small-cell lung cancer (SCLC) is a highly lethal subtype of lung cancer. Despite concerted efforts over the past several decades, there have been limited therapeutic advances. Traditional chemotherapy offers a high response rate and rapid symptomatic improvement, but its benefit is fleeting, and relapse is quick and unforgiving. Immunotherapy has delivered improved outcomes for patients with many cancers and there was compelling rationale for development in SCLC. While initial efforts with cytotoxic T-lymphocyte protein-4 inhibitors failed to improve upon chemotherapy alone, the addition of programmed death ligand-1 (PD-L1) inhibitors to first-line chemotherapy finally provided long-awaited gains in survival. Atezolizumab, when added to carboplatin and etoposide, improved both progression-free survival and overall survival. Durvalumab, when added to platinum plus etoposide, similarly improved OS. Biomarker development has stalled as PD-L1 expression and tumor mutational burden have not been useful predictive biomarkers. However, based on the significant survival improvements, both atezolizumab and durvalumab were approved by the US Food and Drug Administration to be given with first-line chemotherapy, and these regimens represent the new standards of care for SCLC. Copyright (c) The Author(s), 2020. |
546 ## - LANGUAGE NOTE | |
Language note | English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | IN PROCESS -- NOT YET INDEXED |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME | |
Institution | MedStar Washington Hospital Center |
656 ## - INDEX TERM--OCCUPATION | |
Department | Medicine/General Internal Medicine |
657 ## - INDEX TERM--FUNCTION | |
Medline publication type | Journal Article |
657 ## - INDEX TERM--FUNCTION | |
Medline publication type | Review |
700 ## - ADDED ENTRY--PERSONAL NAME | |
Local Authors | Farid, Saira |
790 ## - Authors | |
All authors | Farid S, Liu SV |
856 ## - ELECTRONIC LOCATION AND ACCESS | |
DOI | <a href="https://dx.doi.org/10.1177/1758835920980365">https://dx.doi.org/10.1177/1758835920980365</a> |
Public note | https://dx.doi.org/10.1177/1758835920980365 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
Koha item type | Journal Article |
Item type description | Article |
Withdrawn status | Lost status | Damaged status | Not for loan | Collection | Home library | Current library | Date acquired | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MedStar Authors Catalog | MedStar Authors Catalog | 02/17/2021 | 33414848 | 33414848 | 02/17/2021 | 02/17/2021 | Journal Article |